• Real-world evidence (RWE) research results on treatment utilization and pathways in women with menopausal symptoms via poster presentations on the CHAPTER natural menopause study, CHAPTER i-menopause study and REALISE study
• These poster presentations reinforce Bayer’s leadership and commitment to understanding and advancing women’s healthcare specifically for those who are experiencing menopause symptoms

Key Highlights of Bayer’s presentations at The Menopause Society annual meeting 2023 are:

REALISE iVMS: What do women with breast cancer take for menopause symptoms? A real-world analysis of treatment utilization from the US and Europe

• Approximately 20% of women with vasomotor symptoms (VMS) induced by breast cancer treatment received hormonal therapy (HT).
• Regardless of severity of symptoms, women were prescribed HT at similar rates for their VMS.
• Evidence of HT prescribing, despite contraindications, suggests clinicians are seeking treatment options (indicating significant symptom burden) and an unmet need for non-HT options.

CHAPTER natural menopause: Characterizing treatment pathways for natural menopausal symptoms in US women

• Two-thirds of natural menopausal women did not receive treatment for menopausal symptoms, which might suggest undertreatment in this population.
• Paroxetine was prescribed to fewer women than other non-hormonal therapies , despite being the only non-HT approved for VMS in the US.
• Benzodiazepines were highly prescribed suggesting an unmet need for treatments for the management of menopause-associated sleep and mood disturbances.

CHAPTER i-menopause: Characterizing treatment pathways for endocrine therapy (ET)-related menopausal symptoms in US

• Only one-third of women initiating ET for breast cancer or high breast cancer risk received treatment for menopausal symptoms, which might suggest symptoms often go unrecognized and untreated.
• Benzodiazepines were the most common treatment prescribed, reflecting a requirement for management of menopause-associated sleep and mood disturbances.
• Despite being contraindicated, HT was prescribed to approximately 15% of women, suggesting an unmet need for effective, long-term non-HT management options for ET-related menopausal symptoms.

The research presented showcases the commitment of Bayer as a leader in women’s healthcare to broaden therapeutic choices and to increase awareness and education around menopausal symptoms. Additionally, as part of this commitment, the company is investigating new approaches, including elinzanetant, a late-stage investigational drug with a data readout expected in late 2023.

The official poster session will be held on Thursday, September 28, from 6:15 PM to 7:15 PM EST.